Danaher Corporation vs Health Care Select Sector SPDR Fund — how do they compare? Danaher Corporation trades at $200.37 (market cap $140.88B), while Health Care Select Sector SPDR Fund trades at $158.8. The key difference: Danaher Corporation pays a 0.8% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | XLV | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | — |
52-Week High | $242.05 | $164.48 |
52-Week Low | $161.91 | $129.01 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
XLV trades at $161.41, up 0.35% with a bullish technical signal from moving averages. The healthcare ETF benefits from State Street's upgraded sector outlook and strong performance from holdings like Johnson & Johnson. Technical indicators show the price near pivot point resistance at $162 with ADX signaling strong trend momentum.
Healthcare sector rotation provides tailwinds as investors seek defensive exposure amid tech volatility. Key risks include patent cliffs and regulatory uncertainty, but diversified healthcare exposure offers stability with upcoming dividend distribution in June 2026 supporting total return potential.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →